Opinion statement
Patients presenting with neurologic symptoms and evidence of focal brain disorders should be evaluated immediately. The clinical presentation of focal brain lesions reflects the function in the area of brain involved. Typical symptoms or signs can include motor or sensory deficits, visual complaints, headache, seizures, or changing level of arousal. Initial studies of key importance include magnetic resonance brain imaging with and without a contrast agent such as gadolinium. When clinically safe, lumbar puncture for detailed cerebrospinal fluid (CSF) analysis is very helpful in the differential diagnosis. Combined clinical, radiologic, and diagnostic evaluation of the CSF can often provide solid evidence of the cause of the lesion(s) and may obviate the need for brain biopsy. The status of systemic human immunodeficiency virus (HIV) infection is important in the differential diagnosis, choice of therapy, and prognosis. Thus, concurrent evaluation of the history and status of the HIV infection is vital. Determination of a specific cause of symptomatic focal lesions is important; this should be pursued aggressively unless the global status of the subject suggests that therapy would be futile. With current therapy, many patients presenting with aggressive focal brain lesions can be successfully treated and can return to productive lives.
Similar content being viewed by others
References and Recommended Reading
Berger JR, Donovan Post MJ, Mintz M, et al.: Evaluation and management of intracranial mass lesions in AIDS—report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1998, 50:21–26. Useful review providing expert opinion on this topic and a substantial bibliography.
Antinori A, Ammassari A, De Luca A, et al.: Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 1997, 48:687–694. The largest prospective series addressing diagnosis of focal brain lesions.
Sacktor NC, Lyles RH, McFarlane G, et al.: The changing incidence of HIV-1 related neurologic diseases: 1990–1997. Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health; 1999:145.
Cinque P, Brytting M, Vago L, et al.: Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDSrelated primary lymphoma of the central nervous system. Lancet 1993, 342:398–401.
Eggers C, Gross U, Klinker H, et al.: Limited value of cerebrospinal fluid for direct detection of Toxoplasma gondii in toxoplasmic encephalitis associated with AIDS. J Neurol 1995, 242:644–649.
Schoondermark-Van de Ven E, Galama J, Kraaijeveld C, et al.: Value of the polymerase chain reaction for the detection of Toxoplasma gondii in cerebrospinal fluid from patients with AIDS. Clin Infect Dis 1993, 16:661–666.
Roberts TC, Storch GA: Multiplex PCR for diagnosis of AIDS-related central nervous system lymphoma and toxoplasmosis. J Clin Microbiol 1997, 35:268–269.
Lorberboym M, Wallach F, Estok L, et al.: Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med 1998, 39:1366–1369.
McGuire D, Barhite S, Hollander H, et al.: JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy. Ann Neurol 1995, 37:395–399.
Weber T, Klapper PE, Cleator GM, et al.: Polymerase chain reaction for detection of JC virus DNA in cerebrospinal fluid: a quality control study. J Virol Methods 1997, 69:231–237.
Arribas JR, Clifford DB, Fichtenbaum CJ, et al.: Levels of cytomegalovirus (CMV) DNA in cerebrospinal fluid of patients with AIDS and CMV infection of the central nervous system. J Infect Dis 1995, 172:527–531.
Veenstra J, van Praag RME, Krol A, et al.: Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS 1996, 10:393–399.
Luft BL, Hafner R, Korzun AH, et al.: Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993, 329:995–1000.
Dannemann B, McCutchan JA, Israelski D, et al.: Treatment of toxoplasmic encephalitis in patients with AIDS—a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992, 116:33–43.
Torre D, Casari S, Speranza F, et al.: Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Antimicrob Agents Chemother 1998, 42:1346–1349.
Klepser ME, Klepser TB: Drug treatment of HIV-related opportunistic infections. Drugs 1997, 53:40–73. Helpful source for the therapy of HIV-related opportunistic infection. Bibliographic references to many of the treatments are available in this paper.
Clifford DB, Yiannoutsos C, Glicksman M, et al.: HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999, 52:623–625.
Huang SS, Skolasky RL, Dal Pan GJ, et al.: Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 1998, 4:324–332.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Clifford, D.B. Focal brain lesions in people with HIV. Curr Treat Options Neurol 1, 167–172 (1999). https://doi.org/10.1007/s11940-999-0016-6
Issue Date:
DOI: https://doi.org/10.1007/s11940-999-0016-6